In vitro studies have shown that extracellular Ca2+ combined with CaSR expressed by tumor cells activate AKT and MAPK pathways to enhance migration and proliferation of cancer cells, whilst application of CaSR antagonists to interfere with renal cancer in mice significantly reduced the incidence of bone metastasis (82). The gene discussed is CASR; the disease is renal carcinoma.